Skip to main content
Clinical Trials/NCT06018415
NCT06018415CompletedNot Applicable

Effects of Early and Late Time-restricted Eating on Overweight Adults With Metabolic Syndrome

First Affiliated Hospital Xi'an Jiaotong University1 site in 1 country103 target enrollmentStarted: May 7, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
103
Locations
1
Primary Endpoint
Changes in abdominal fat area

Study Overview

Brief Summary

Investigators aim to compare the effects of early and late time-restricted feeding on overweight adults with metabolic syndrome

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age from 18 to 65 years
  • •Body mass index (BMI): 24.0-40.0 kg/m2
  • •Diagnosed with metabolic syndrome (i.e., more than 3 abnormal findings out of 5):
  • •Waist circumference ≥ 90 cm (men) or ≥ 80 cm (women).
  • •Elevated triglyceride (TG) (use of lipid-lowering medication is an alternate indicator) ≥ 150 mg/dL (1.7 mmol/L).
  • •Reduced high-density lipoprotein cholesterol (HDL-c) (use of lipid-lowering medication is an alternate indicator) < 40 mg/dL (1.0 mmol/L) in males < 50 mg/dL (1.3 mmol/L) in females.
  • •Elevated blood pressure (use of antihypertensive medication is an alternate indicator). Systolic blood pressure (SBP) ≥ 130 and/or diastolic blood pressure (DBP) ≥ 85 mmHg.
  • •Elevated fasting blood glucose (FBG) (used of hypoglycemic medications is an alternate indicator) ≥ 100 mg/dL (5.6 mmol/L).

Exclusion Criteria

  • •Unstable weight (change > 10% current body weight) for 3 months prior to the study
  • •Pregnant or breast-feeding
  • •Night shift workers
  • •History of major diseases or related diseases, such as cancer, inflammatory disease, chronic obstructive pulmonary disease and major adverse cardiovascular event
  • •Active viral hepatitis, acquired immune deficiency syndrome, syphilis and other sexually transmitted diseases, tuberculosis and other infectious diseases
  • •Being treated with antibiotics or corticosteroids
  • •Current participate in other weight-management program, current on a prescribed diet for special disease or current on any drugs that effect appetite
  • •The researcher deemed it inappropriate to participate in the experimenter.

Arms & Interventions

Early time-restricted eating (eTRE)

Experimental

The eTRE group is instructed to consume all calories from 7 AM to 3 PM each day and fast from 3 PM to 7 AM

Intervention: Early time-restricted eating (eTRE) (Behavioral)

Late time-restricted eating (lTRE)

Experimental

The lTRE group is instructed toconsume all calories from 11 AM to 7 PM each day and fast from 7 PM to 11 PM

Intervention: Late time-restricted eating (lTRE) (Behavioral)

Outcomes

Primary Outcomes

Changes in abdominal fat area

Time Frame: 0-week; 6-week and 12-week

Abdominal fat area is measured using bioelectrical impedance analysis (OMRON MEDICAL Beijing Co., Ltd. DUALSCAN, HDS-2000) to the nearest 1 cm2.

Changes in body weight

Time Frame: 0-week; 6-week and 12-week

Body weight is assessed at the research center with the participants without shoes and in light clothing using a digital scale (OMRON MEDICAL Beijing Co., Ltd. HNH-318) to the nearest 0.1 kg.

Secondary Outcomes

  • Changes in total cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c)(0-week; 6-week and 12-week)
  • Changes in uric acid (UA)(0-week; 6-week and 12-week)
  • Changes in blood pressure.(0-week; 6-week and 12-week)
  • Changes in body composition ( body fat mass)(0-week and 12-week)
  • Changes in body composition (body muscle mass)(0-week and 12-week)
  • Changes in body composition ( body fat mass)(0-week and 12-week)
  • Changes in body composition (body muscle mass)(0-week and 12-week)
  • Changes in glycemic control(0-week; 6-week and 12-week (glucose and insulin)0-week and 12-week (HbA1c))
  • Changes in hemoglobin A1c (HbA1c)(0-week; 6-week and 12-week (glucose and insulin)0-week and 12-week (HbA1c))
  • Changes in total cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c)(0-week; 6-week and 12-week)
  • Changes in uric acid (UA)(0-week; 6-week and 12-week)
  • Changes in blood pressure.(0-week; 6-week and 12-week)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials